Kuros Biosciences Sales Jump 72%, Yet Stock Near 52-Week Low Amid Trust Deficit

Despite 72% revenue growth to $146.1M and ambitious trauma market entry, Kuros Biosciences stock trades near 52-week low, 31% down YTD, as market awaits proof of scalable execution.

Despite reporting a 72% surge in full-year revenue to $146.1 million and unveiling an ambitious expansion into the trauma market, Kuros Biosciences finds its shares trading just above a 52-week low. The stock closed at €20.66 on Thursday, up a modest 2.38% from the previous session, but remains 31% lower year-to-date — a stark contrast to the operational momentum the company showcased at its recent capital markets presentation in Zurich.

At the investor day, CEO Chris Fair and President Joost de Bruijn detailed how MagnetOs, the company’s bone graft substitute, is moving beyond its core spinal applications. The product is now being pushed into foot and ankle procedures and, more notably, the trauma segment for acute fracture healing. To support this push, Kuros has opened a new 50,000-square-foot US headquarters in Alpharetta, Georgia, with production slated to begin in August — a milestone the company views as critical for capturing a share of the estimated $1.8 billion foot and ankle market by 2032.

Management laid out an ambitious financial roadmap: at least 35% revenue growth in 2026, with an adjusted EBITDA margin of around 14%. By 2028, the company targets revenue of $300 million to $330 million, alongside a margin of at least 20%. Direct MagnetOs sales climbed 71% to $143.9 million last year, and the adoption of the product in minimally invasive procedures is accelerating. The company plans to back this progress with data from ongoing Level-I human trials across multiple indications.

The stock’s technical indicators, however, paint a picture of deep skepticism. With a relative strength index of 40.4, shares are hovering near oversold territory, while annualized volatility has hit 71%. The stock is trading 25% below its 200-day moving average of €27.71 and well off its 50-day average of €23.30. Analysts currently forecast earnings per share of $0.311 for the current year. The next major catalyst will be the second-quarter results, due in mid-August, which are expected to shed light on operating efficiency and the pace of the US expansion.

The disconnect between operational delivery and market valuation raises a fundamental question: does the market doubt the sustainability of Kuros’s growth, or is it simply waiting for proof that the company can execute at scale? Fair described MagnetOs as having built “a strong foundation in the spine,” with room to expand into adjacent markets. The coming months — especially after the Alpharetta plant goes live — will test whether that foundation is sturdy enough to support the valuation the company believes it deserves.